NEO
NeoGenomics, Inc.NASDAQHealthcare$8.00+0.25%ClosedMarket Cap: $207.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.25
P/S
0.29
EV/EBITDA
-13.48
DCF Value
$-151.23
FCF Yield
-10.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
42.2%
Operating Margin
-15.6%
Net Margin
-14.9%
ROE
-12.6%
ROA
-7.9%
ROIC
-8.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $190.2M | 39.8% | $-11.1M | $-9.9M | $-0.38 | — |
| FY 2025 | $727.3M | 38.8% | $-66.1M | $-108.0M | $-4.20 | — |
| Q3 2025 | $187.8M | 42.8% | $-27.0M | $-27.1M | $-1.05 | — |
| Q2 2025 | $181.3M | 42.6% | $-47.6M | $-45.1M | $-1.75 | — |
| Q1 2025 | $168.0M | 43.6% | $-27.8M | $-25.9M | $-1.00 | — |
| Q4 2024 | $172.0M | 44.9% | $-18.4M | $-15.3M | $-0.60 | — |
| FY 2024 | $660.6M | 43.9% | $-92.1M | $-78.7M | $-3.10 | — |
| Q3 2024 | $167.8M | 44.6% | $-21.2M | $-17.7M | $-0.70 | — |
| Q2 2024 | $164.5M | 44.1% | $-21.9M | $-18.6M | $-0.75 | — |
| Q1 2024 | $156.2M | 41.9% | $-30.6M | $-27.1M | $-1.05 | — |
| Q4 2023 | $155.6M | 43.5% | $-18.6M | $-14.3M | $-0.55 | — |
| FY 2023 | $591.6M | 41.3% | $-107.7M | $-88.0M | $-3.50 | — |